Sign in
Active, not recruitingPhase 3

Dronabinol After Arthroscopic Surgery

Key facts

Who runs it
Northwestern University
Where
Chicago, United StatesSee the site
Trial code
Status
Active, not recruiting
Phase
Phase 3
People taking part
30 people, planned
Started
28 Jun 2022
Expected to end
Jun 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Dronabinol
  • Placebo
Record updated
25 September 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (16)Hide the full registry criteria

Who can take part

  • Age 18 years or older
  • Patient who will undergo arthroscopic surgery of the knee including, but not limited to,; Meniscectomy; Synovectomy; Chondroplasty; Loose body removal

Who cannot take part

  • Revision surgery
  • Open surgery
  • Comorbidities preventing surgery
  • Patients taking any of the following drugs or supplements; Anticholinergic agents; Benzodiazepines; Central nervous system depressants; Droperidol; Hydroxyzine; Levomepromazine or methotrimeprazine; Monoamine oxidase inhibitors; Ritonavir; Selective serotonin reuptake inhibitors; Sympathomimetics; St. John's Wort
  • Current diagnosed alcohol or drug abuse
  • Patients who cannot or will not abide by the medication restrictions listed below; Medication restrictions
  • Participants should not drink alcohol or take other drugs while taking the study drug or hydrocodone/acetaminophen
  • Patients with an allergy to any of the study drugs
  • Patients with a history of mania, depression, or schizophrenia
  • Patients under age 18 years
  • Patients who cannot provide consent
  • Patients who are pregnant, breast feeding, or are trying to become pregnant during the study period
  • Patient who are lactose-intolerant
  • Participants must agree to abstain from using recreational or medical marijuana products or cannabidiol (CBD) in any form during the treatment period

Where in United States

  • Northwestern University Feinberg School of MedicineChicago, United States

About the trial

What the trial wants to find out

The purpose of the proposed study is to evaluate the efficacy of dronabinol for postoperative pain after arthroscopic surgery of the knee. The investigators hypothesize that dronabinol will relieve pain, reduce opioid consumption and will result in few negative side effects. If this pilot study shows promising results the investigators will expand the trial to include additional arthroscopic surgeries (hip, shoulder) and other types of orthopaedic surgery.

The 2 groups in the trial

  • DronabinolTreatment being tested

    Patients will received dronabinol (5mg) twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery

  • PlaceboPlacebo, for comparison

    Patients will received placebo twice a day for 7 days in addition to standard pain medication protocol after arthroscopic knee surgery

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Dronabinol for the Treatment of Postoperative Pain After Arthroscopic Surgery: a Pilot Randomized Trial
Record updated
25 September 2026